Cong Xing

6PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pacific Peoples social determinants of healthMolecular targetsInnate immunityInstrumental methods (excl. immunological and bioassay methods)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 14, 2026
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism.

|Mar 04, 2026
PARP7 protects the lung epithelial barrier from diverse environmental threats.

Devon Jeltema, Kun Yang, Joshua J Baty

|May 06, 2025
Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer.

Cong Xing, Xintao Tu, Wanwan Huai

|Mar 07, 2025
Dynamic STING repression orchestrates immune cell development and function.

Kennady Knox, Devon Jeltema, Nicole Dobbs

|Feb 19, 2025
PARP7 inhibits type I interferon signaling to prevent autoimmunity and lung disease.

Devon Jeltema, Kennady Knox, Nicole Dobbs

|Nov 15, 2022
Interruption of post-Golgi STING trafficking activates tonic interferon signaling.

Xintao Tu, Ting-Ting Chu, Devon Jeltema

Pageof 1

Frequent Collaborators

5 joint publications

Devon Jeltema

5 joint publications

Kun Yang

5 joint publications

Nan Yan

4 joint publications

Kennady Knox